VACCINEX, INC. (VCNX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US9186401033
VACCINEX, INC. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 601,000.00 USD | 2.10 m USD |
| Gross profit | – | 2.06 m USD |
| Operating income | -18.74 m USD | -5.23 m USD |
| EBIT | -18.63 m USD | – |
| Net income | -18.63 m USD | -5.26 m USD |
| Diluted EPS – continuing operations | -8.88 USD | – |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About VACCINEX, INC.
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 clinical for the treatment of Alzheimer's disease and has completed phase 2 study for the treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer; Pepinemab in combination with Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 clinical trial with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab and/or Ipilimumab which is in phase 2 clinical trial for melanoma; Pepinemab in combination with Trastuzumab and dendritic cell vaccines in phase 2 clinical trial for breast cancer. The company has also developed ActivMAb, a human antibody discovery platform based on a novel method for expressing and presenting complex multipass membrane proteins, as well as full-length human monoclonal antibodies on the surface of mammalian pox viruses. In addition, it develops CHS-114 and anti-CCR8 antibody; and VX5, which is in preclinical development to treat related to autoimmune disorders.It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; Emory University; Huntington Study Group; Catalent Pharma Solutions, LLC; and Surface Oncology, Inc. The company was incorporated in 2001 and is headquartered in Rochester, New York.
More stocks
- authID Inc. (AUID)
- FARMHOUSE, INC. /NV (FMHS)
- Vivos Therapeutics, Inc. (VVOS)
- KwikClick, Inc. (KWIK)
- ADIAL PHARMACEUTICALS, INC. (ADIL)
- CAPSTONE COMPANIES, INC. (CAPC)
- Toppoint Holdings Inc. (TOPP)
- PRINCETON CAPITAL CORP (PIAC)
- BIOXYTRAN, INC (BIXT)
- CEA Industries Inc. (BNC)
- AIBOTICS, INC. (AIBT)
- Q/C TECHNOLOGIES, INC. (QCLS)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.